|
WO2001040800A2
(en)
*
|
1999-11-30 |
2001-06-07 |
Parker Hughes Institute |
Syk localized at centrosome
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US20040171062A1
(en)
*
|
2002-02-28 |
2004-09-02 |
Plexxikon, Inc. |
Methods for the design of molecular scaffolds and ligands
|
|
IL166241A0
(en)
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
|
AU2003272548A1
(en)
*
|
2002-09-16 |
2004-04-30 |
Plexxikon, Inc. |
Crystal structure of pim-1 kinase
|
|
US20050282814A1
(en)
*
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
US7456190B2
(en)
*
|
2003-03-13 |
2008-11-25 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as protein kinase inhibitors
|
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
EP1644365A2
(en)
*
|
2003-07-02 |
2006-04-12 |
Biofocus Discovery Ltd |
Pyrazine and pyridine derivatives as rho kinase inhibitors
|
|
EP1648875A1
(en)
*
|
2003-07-30 |
2006-04-26 |
Cyclacel Limited |
2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
|
|
ES2421139T3
(es)
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
|
US7572914B2
(en)
*
|
2003-12-19 |
2009-08-11 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
AU2005231507B2
(en)
|
2004-04-08 |
2012-03-01 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
|
WO2005105788A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Takeda San Diego, Inc. |
Indole derivatives and use thereof as kinase inhibitors
|
|
EP1751133B1
(en)
*
|
2004-04-28 |
2010-04-14 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of rock and other protein kinases
|
|
ES2897422T3
(es)
|
2004-05-14 |
2022-03-01 |
Vertex Pharma |
Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
|
|
WO2006023931A2
(en)
*
|
2004-08-18 |
2006-03-02 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
NZ588896A
(en)
|
2004-08-25 |
2012-05-25 |
Targegen Inc |
Heterocyclic compounds and methods of use
|
|
WO2006034207A2
(en)
*
|
2004-09-17 |
2006-03-30 |
Vanderbilt University |
Use of gsk3 inhibitors in combination with radiation therapies
|
|
EP1812439B2
(en)
|
2004-10-15 |
2017-12-06 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
US7968574B2
(en)
*
|
2004-12-28 |
2011-06-28 |
Kinex Pharmaceuticals, Llc |
Biaryl compositions and methods for modulating a kinase cascade
|
|
US7449458B2
(en)
|
2005-01-19 |
2008-11-11 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
BRPI0607062A2
(pt)
|
2005-02-28 |
2009-08-04 |
Japan Tobacco Inc |
composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2006133411A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Targegen, Inc. |
Methods and compositions for the treatment of ocular disorders
|
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
|
EP1896134A2
(en)
|
2005-06-13 |
2008-03-12 |
Rigel Pharmaceuticals, Inc. |
Methods and compositions for treating degenerative bone disorders
|
|
ES2279500T3
(es)
*
|
2005-06-17 |
2007-08-16 |
Magneti Marelli Powertrain S.P.A. |
Inyector de carburante.
|
|
JP2009501721A
(ja)
*
|
2005-07-12 |
2009-01-22 |
アカディア ファーマシューティカルズ インコーポレイテッド |
レチノイン酸受容体における活性を伴う化合物
|
|
CN101253152A
(zh)
*
|
2005-09-02 |
2008-08-27 |
安斯泰来制药株式会社 |
作为rock抑制剂的酰胺衍生物
|
|
US7512864B2
(en)
*
|
2005-09-30 |
2009-03-31 |
Josef Zeevi |
System and method of accessing non-volatile computer memory
|
|
US8119655B2
(en)
*
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
AU2006304897B2
(en)
|
2005-10-18 |
2012-07-12 |
Janssen Pharmaceutica N.V. |
Method of inhibiting FLT3 kinase
|
|
WO2007053452A1
(en)
|
2005-11-01 |
2007-05-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
US20070149508A1
(en)
*
|
2005-11-02 |
2007-06-28 |
Targegen, Inc. |
Six membered heteroaromatic inhibitors targeting resistant kinase mutations
|
|
EA200870217A1
(ru)
|
2006-01-30 |
2009-02-27 |
Экселиксис, Инк. |
4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
|
|
WO2007098507A2
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US7834178B2
(en)
*
|
2006-03-01 |
2010-11-16 |
Bristol-Myers Squibb Company |
Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
|
|
US8133867B2
(en)
|
2006-03-20 |
2012-03-13 |
Seikagaku Corporation |
Method for treating rheumatoid arthritis with an antibody that binds to a hepatocyte growth factor receptor
|
|
AU2007231547B2
(en)
*
|
2006-03-29 |
2012-07-12 |
Velacor Therapeutics Pty Ltd |
Treatment of neurodegenerative diseases
|
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
|
EP2016070B1
(en)
|
2006-04-20 |
2016-01-13 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
|
KR101367645B1
(ko)
|
2006-04-20 |
2014-02-27 |
얀센 파마슈티카 엔.브이. |
C-fms 키나제의 저해제로서의 복소환식 화합물
|
|
JP5564251B2
(ja)
|
2006-06-29 |
2014-07-30 |
キネックス ファーマシューティカルズ, エルエルシー |
キナーゼカスケードを調節するためのビアリール組成物および方法
|
|
WO2008008234A1
(en)
|
2006-07-07 |
2008-01-17 |
Targegen, Inc. |
2-amino-5-substituted pyrimidine inhibitors
|
|
EP2223925A1
(en)
*
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
JP2010505962A
(ja)
|
2006-10-09 |
2010-02-25 |
武田薬品工業株式会社 |
キナーゼ阻害剤
|
|
US20080153822A1
(en)
*
|
2006-11-30 |
2008-06-26 |
Martin Augustin |
Methods of treating pain
|
|
US7935697B2
(en)
|
2006-12-28 |
2011-05-03 |
Kinex Pharmaceuticals, Llc |
Compositions for modulating a kinase cascade and methods of use thereof
|
|
HUE029188T2
(en)
|
2007-03-12 |
2017-03-28 |
Ym Biosciences Australia Pty |
Phenylamino-pyrimidine compounds and their use
|
|
WO2008119109A1
(en)
|
2007-03-29 |
2008-10-09 |
Velacor Therapeutics Pty Ltd |
Treatment of neurological disorders
|
|
US8445686B2
(en)
|
2007-08-27 |
2013-05-21 |
Abbvie Inc. |
4-(4-pyridinyl)-benzamides and their use as rock activity modulators
|
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
|
HRP20170317T1
(hr)
|
2008-02-15 |
2017-04-21 |
Rigel Pharmaceuticals, Inc. |
Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
|
|
US20110189308A1
(en)
*
|
2008-03-17 |
2011-08-04 |
Asa Abeliovich |
Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
BRPI0910668A2
(pt)
|
2008-04-22 |
2019-09-24 |
Portola Pharmaceutiacals Inc |
inibidores de proteína quinases
|
|
EP2285989B1
(en)
|
2008-05-15 |
2016-11-16 |
The University of North Carolina At Chapel Hill |
Novel targets for regulation of angiogenesis
|
|
US8263547B2
(en)
|
2008-05-28 |
2012-09-11 |
Massachusetts Institute Of Technology |
DISC-1 pathway activators in the control of neurogenesis
|
|
WO2010068863A2
(en)
|
2008-12-12 |
2010-06-17 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
PE20120325A1
(es)
*
|
2009-05-19 |
2012-04-12 |
Dow Agrosciences Llc |
Aminopirimidinas sustituidas con arilo como agentes fungicidas
|
|
EP2516434B1
(en)
|
2009-12-23 |
2015-05-27 |
Takeda Pharmaceutical Company Limited |
Fused heteroaromatic pyrrolidinones as syk inhibitors
|
|
US9109227B2
(en)
|
2010-01-05 |
2015-08-18 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
FLT3 receptor antagonists for the treatment or the prevention of pain disorders
|
|
CN102812022B
(zh)
|
2010-01-12 |
2016-02-03 |
Ab科学有限公司 |
噻唑和噁唑激酶抑制剂
|
|
US8334292B1
(en)
|
2010-06-14 |
2012-12-18 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
WO2012050921A2
(en)
*
|
2010-09-28 |
2012-04-19 |
Nono, Inc. |
Nd2 peptides and methods of treating neurological disease
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
|
AU2011328237A1
(en)
*
|
2010-11-09 |
2013-05-23 |
Cellzome Limited |
Pyridine compounds and aza analogues thereof as TYK2 inhibitors
|
|
ES2716865T3
(es)
|
2011-02-18 |
2019-06-17 |
Scripps Research Inst |
Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
|
|
WO2012177714A1
(en)
|
2011-06-22 |
2012-12-27 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
|
DE102011112978A1
(de)
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
Benzonitrilderivate
|
|
EP2782579B1
(en)
|
2011-11-23 |
2019-01-02 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
|
SG11201406584TA
(en)
|
2012-04-24 |
2014-11-27 |
Vertex Pharma |
Dna-pk inhibitors
|
|
US8809359B2
(en)
|
2012-06-29 |
2014-08-19 |
Ym Biosciences Australia Pty Ltd |
Phenyl amino pyrimidine bicyclic compounds and uses thereof
|
|
AU2013299922B2
(en)
|
2012-08-07 |
2018-06-21 |
Janssen Pharmaceutica Nv |
Process for the preparation of heterocyclic ester derivatives
|
|
ES2607807T3
(es)
|
2012-08-07 |
2017-04-04 |
Janssen Pharmaceutica Nv |
Procedimiento para la preparación de los inibidores de las quinasas c-fms
|
|
CN102827085A
(zh)
*
|
2012-09-17 |
2012-12-19 |
符爱清 |
2,4,5-三氯嘧啶化合物的制备方法
|
|
JP6407504B2
(ja)
|
2012-09-21 |
2018-10-17 |
アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. |
恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
BR112015016282A2
(en)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals, Inc. |
crenolanib for treatment of mutated flt3 proliferative disorders
|
|
RS62649B1
(sr)
|
2013-03-12 |
2021-12-31 |
Vertex Pharma |
Inhibitori dnk-pk
|
|
KR102411227B1
(ko)
|
2013-10-17 |
2022-06-21 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
|
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
|
DK3063143T3
(en)
*
|
2013-11-01 |
2018-08-20 |
Novartis Ag |
Amino heteroaryl benzamides as kinase inhibitors
|
|
USRE50030E1
(en)
|
2013-12-13 |
2024-07-02 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
EP3079682A4
(en)
|
2013-12-13 |
2017-08-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
TWI681954B
(zh)
|
2014-06-12 |
2020-01-11 |
美商西爾拉癌症醫學公司 |
N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
|
|
BR112017002001B1
(pt)
|
2014-07-31 |
2022-10-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compostos e composição farmacêutica
|
|
US11202817B2
(en)
*
|
2014-08-18 |
2021-12-21 |
Cornell University |
Dipeptidomimetics as inhibitors of human immunoproteasomes
|
|
CA2965178C
(en)
|
2014-10-22 |
2023-09-26 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
US10227328B2
(en)
|
2015-02-04 |
2019-03-12 |
Beyondbio Inc. |
Heterocyclic compound and pharmaceutical composition comprising same
|
|
HUE057041T2
(hu)
|
2015-07-06 |
2022-04-28 |
Alkermes Inc |
Hiszton deacetiláz hetero-halogén gátlói
|
|
WO2017007755A1
(en)
|
2015-07-06 |
2017-01-12 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
EP3254698A1
(en)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
|
|
MX394860B
(es)
|
2016-09-27 |
2025-03-24 |
Vertex Pharma |
Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
|
|
US12534764B2
(en)
|
2016-11-02 |
2026-01-27 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
|
|
US12662706B2
(en)
|
2016-11-02 |
2026-06-23 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
|
|
KR20180074792A
(ko)
|
2016-11-02 |
2018-07-03 |
아로그 파마슈티칼스, 인코퍼레이티드 |
돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙
|
|
HRP20220223T1
(hr)
|
2017-01-11 |
2022-04-29 |
Alkermes, Inc. |
Biciklički inhibitori histon deacetilaze
|
|
WO2018203219A1
(en)
|
2017-05-02 |
2018-11-08 |
Novartis Ag |
Combination therapy
|
|
WO2018211018A1
(en)
|
2017-05-17 |
2018-11-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
|
WO2018217766A1
(en)
|
2017-05-22 |
2018-11-29 |
Whitehead Institute For Biomedical Research |
Kcc2 expression enhancing compounds and uses thereof
|
|
US11225475B2
(en)
|
2017-08-07 |
2022-01-18 |
Alkermes, Inc. |
Substituted pyridines as inhibitors of histone deacetylase
|
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
|
CN110833551B
(zh)
*
|
2018-08-15 |
2023-03-24 |
广西梧州制药(集团)股份有限公司 |
吡唑并嘧啶衍生物在治疗急性胰腺炎的用途
|
|
RS66346B1
(sr)
|
2018-10-22 |
2025-01-31 |
Alumis Inc |
Inhibitori tyk2 i njihova upotreba
|
|
US12208098B2
(en)
|
2018-11-26 |
2025-01-28 |
Gachon University Of Industry-Academic Cooperation Foundation |
4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof
|
|
WO2020163812A1
(en)
|
2019-02-08 |
2020-08-13 |
Frequency Therapeutics, Inc. |
Valproic acid compounds and wnt agonists for treating ear disorders
|
|
EP4563150A3
(en)
|
2019-05-13 |
2025-07-23 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
|
|
WO2022019998A1
(en)
|
2020-07-20 |
2022-01-27 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
|
IL301385A
(en)
|
2020-09-16 |
2023-05-01 |
Alumis Inc |
TYK2 inhibitors and their use
|
|
US11969420B2
(en)
|
2020-10-30 |
2024-04-30 |
Arog Pharmaceuticals, Inc. |
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
|
|
WO2022090547A1
(en)
|
2020-10-30 |
2022-05-05 |
Dsm Ip Assets B.V. |
Production of carotenoids by fermentation
|
|
CN115677595B
(zh)
*
|
2022-10-26 |
2024-06-14 |
江苏睿实生物科技有限公司 |
一种2,4,5-三氯嘧啶的制备方法
|
|
CN116751191B
(zh)
*
|
2023-05-19 |
2025-09-16 |
凌科药业(杭州)有限公司 |
一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
|
|
KR20250075302A
(ko)
*
|
2023-11-21 |
2025-05-28 |
(주)신테카바이오 |
크레놀라닙 또는 이의 약학적으로 허용 가능한 염을 포함하는 아토피 피부염의 예방 또는 치료용 조성물
|
|
WO2025221087A1
(ko)
*
|
2024-04-19 |
2025-10-23 |
인제대학교 산학협력단 |
피디케이원 조절제 화합물 및 그를 포함하는 조성물
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|